Landmark findings from a major malaria clinical trial led by Menzies School of Health Research (Menzies) and international collaborators have confirmed the safety and effectiveness of two Plasmodium vivax (P. vivax) malaria medications in G6PD-normal patients—high-dose primaquine and single-dose tafenoquine—supporting more efficient treatment regimens to address the liver stage of the disease.